Global Clinical Consequences of Poor Adherence

  • Sylvie PerreaultEmail author
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)


The chapter on healthcare consequences of non-adherence initially presents the thematic of global prevalence and healthcare costs of uncontrolled hypertension, followed by the clinical consequences of non-adherence to antihypertensive drugs. Drug adherence is a complex phenomenon and may be influenced by many factors, one of which is the coexistence of other chronic diseases. Thus, a discussion exposing the relationship of drug adherence with the presence of associated morbidities is presented. Subsequently, an overview of the risk prediction and the population impact of implementing guidelines and interventions on drug adherence are depicted. The discussion is further followed by the technology advances and healthcare reform efforts creating an opportunities to reshape the current system where evidence generated from observational studies could contribute to better meet stakeholder needs. Several considerations of the clinical consequences of healthcare professional and system on drug adherence are introduced. Finally, the last section considers the clinical consequences of implementing patient-centered approaches and personalized evaluations of adherence to antihypertensive drugs, as well as the clinical consequences of changes to healthcare professional- and policy-related factors on adherence.


Adherence Outcomes Comorbidities Population level Personalized care and policy 


  1. 1.
    World Health Organization. A global brief on hypertension. Silent killer, global public health crisis. 2016.Google Scholar
  2. 2.
    NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37–55.CrossRefGoogle Scholar
  3. 3.
    World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization; 2009. p. 1–62.Google Scholar
  4. 4.
    Heidenreich PA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Gaziano TA, Bitton A, Anand S, Weinstein MC, International Society of Hypertension. The global cost of nonoptimal blood pressure. J Hypertens. 2009;27:1472–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Townsend N, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37:3232–45.PubMedCrossRefGoogle Scholar
  7. 7.
    World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.Google Scholar
  8. 8.
    Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Lewanczuk R. Innovations in primary care: implication for hypertension detection and treatment. Can J Cardiol. 2006;22:614–6.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Gee ME, et al. Antihypertensive medication use, adherence, stops, and starts in Canadians with hypertension. Can J Cardiol. 2012;28:383–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Wolf-Maier K, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043–50.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Egan BM, Zhao Y. Different definitions of prevalent hypertension impact: the clinical epidemiology of hypertension and attainment of Healthy People goals. J Clin Hypertens (Greenwich). 2013;15:154–61.CrossRefGoogle Scholar
  14. 14.
    Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046–58.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Resnick HE, Shorr RI, Kuller L, Franse L, Harris TB. Prevalence and clinical implications of American Diabetes Association-defined diabetes and other categories of glucose dysregulation in older adults: the health, aging and body composition study. J Clin Epidemiol. 2001;54:869–76.PubMedCrossRefGoogle Scholar
  16. 16.
    Smith NL, et al. Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study. J Am Geriatr Soc. 2002;50:416–23.PubMedCrossRefGoogle Scholar
  17. 17.
    de Rekeneire N, et al. Racial differences in glycemic control in a well-functioning older diabetic population: findings from the Health, Aging and Body Composition Study. Diabetes Care. 2003;26:1986–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc. 2007;55:1056–65.PubMedCrossRefGoogle Scholar
  19. 19.
    Robinson JG, Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol. 2010;4:483–90.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Egan BM, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62:691–7.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27:1610–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Mennini FS, et al. Cost of poor adherence to anti-hypertensive therapy in five European countries. Eur J Health Econ. 2015;16:65–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Lim SS, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Breekveldt-Postma NS, et al. Effect of persistent use of antihypertensives on blood pressure goal attainment. Curr Med Res Opin. 2008;24:1025–31.PubMedCrossRefGoogle Scholar
  25. 25.
    LaFleur J, Oderda GM. Methods to measure patient compliance with medication regimens. J Pain Palliat Care Pharmacother. 2004;18:81–7.PubMedCrossRefGoogle Scholar
  26. 26.
    McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36:1331–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Shin S, et al. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients. Hypertens Res. 2013;36:1000–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69–75.PubMedCrossRefGoogle Scholar
  29. 29.
    Krousel-Wood MA, Muntner P, He J, Whelton PK. Primary prevention of essential hypertension. Med Clin North Am. 2004;88:223–38.PubMedCrossRefGoogle Scholar
  30. 30.
    Chobanian AV, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10:348–54.CrossRefGoogle Scholar
  32. 32.
    DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794–811.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Lawes CM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–8.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Blood Pressure Lowering Treatment Trialists’ Collaboration, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121–3.PubMedCentralGoogle Scholar
  36. 36.
    Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess. 2003;7:1–94.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Burke TA, et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens. 2006;24:1193–200.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Benner JS, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455–61.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Perreault S, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol. 2005;61:667–74.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Perreault S, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother. 2005;39:1401–8.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Perreault S, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol. 2005;59:564–73.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Simard P, et al. Persistence and adherence to oral antidiabetics: a population-based cohort study. Acta Diabetol. 2015;52:547–56.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–7.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Mazzaglia G, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23:2093–100.CrossRefPubMedGoogle Scholar
  46. 46.
    Sung SK, et al. First-year treatment adherence among outpatients initiating antihypertensive medication in Korea: results of a retrospective claims review. Clin Ther. 2009;31:1309–20.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521–30.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Liu L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res. 2009;32:1032–40.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Ho PM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772–9.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62:76–87.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Dragomir A, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48:418–25.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16:568–76.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Wu PH, et al. Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. Am J Hypertens. 2010;23:155–60.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Mazzaglia G, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598–605.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Perreault S, et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol. 2010;69:74–84.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Kettani FZ, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40:213–20.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Perreault S, et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med. 2009;266:207–18.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Perreault S, et al. Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes. Neurology. 2012;79:2037–43.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Wong MC, et al. Drug adherence and the incidence of coronary heart disease- and stroke-specific mortality among 218,047 patients newly prescribed an antihypertensive medication: a five-year cohort study. Int J Cardiol. 2013;168:928–33.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Kim S, et al. Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications. Hypertension. 2016;67:506–12.PubMedGoogle Scholar
  61. 61.
    Schafer HH, Scheunert U. Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care. Swiss Med Wkly. 2013;143:w13854.PubMedGoogle Scholar
  62. 62.
    Roy L, et al. Adherence to antihypertensive agents improves risk reduction of end-stage renal disease. Kidney Int. 2013;84:570–7.PubMedCrossRefGoogle Scholar
  63. 63.
    van der Laan MJ, Polley EC, Hubbard AE. Super learner. Stat Appl Genet Mol Biol. 2007;6:Article25.Google Scholar
  64. 64.
    Obermeyer Z, Emanuel EJ. Predicting the future—big data, machine learning, and clinical medicine. N Engl J Med. 2016;375:1216–9.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Kennedy EH, Ma Z, McHugh MD, Small DS. Nonparametric methods for doubly robust estimation of continuous treatment effects. J R Stat Soc Ser B. 2017;79(4):1229–45.CrossRefGoogle Scholar
  66. 66.
    Krousel-Wood M, et al. Association of depression with antihypertensive medication adherence in older adults: cross-sectional and longitudinal findings from CoSMO. Ann Behav Med. 2010;40:248–57.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31:1925–38.CrossRefGoogle Scholar
  68. 68.
    Ghembaza MA, Senoussaoui Y, Tani MK, Meguenni K. Impact of patient knowledge of hypertension complications on adherence to antihypertensive therapy. Curr Hypertens Rev. 2014;10:41–8.PubMedCrossRefGoogle Scholar
  69. 69.
    An J, Nichol MB. Multiple medication adherence and its effect on clinical outcomes among patients with comorbid type 2 diabetes and hypertension. Med Care. 2013;51:879–87.PubMedCrossRefGoogle Scholar
  70. 70.
    Carretero OA, Oparil S. Essential hypertension: part II: treatment. Circulation. 2000;101:446–53.PubMedCrossRefGoogle Scholar
  71. 71.
    Scalco AZ, Scalco MZ, Azul JB, Lotufo Neto F. Hypertension and depression. Clinics (Sao Paulo). 2005;60:241–50.CrossRefGoogle Scholar
  72. 72.
    Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed. 2007;9:58.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Jamous RM, et al. Adherence and satisfaction with oral hypoglycemic medications: a pilot study in Palestine. Int J Clin Pharm. 2011;33:942–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Ahmad NS, Ramli A, Islahudin F, Paraidathathu T. Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia. Patient Prefer Adherence. 2013;7:525–30.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Simard P, et al. Impact of adherence to oral antidiabetics on all-cause mortality: a population based study. Value Health. 2015;18:A611.PubMedCrossRefGoogle Scholar
  76. 76.
    Dunlay SM, Eveleth JM, Shah ND, McNallan SM, Roger VL. Medication adherence among community-dwelling patients with heart failure. Mayo Clin Proc. 2011;86:273–81.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Wu JR, Lennie TA, Dekker RL, Biddle MJ, Moser DK. Medication adherence, depressive symptoms, and cardiac event-free survival in patients with heart failure. J Card Fail. 2013;19:317–24.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Perreault S, et al. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. Pharmacoepidemiol Drug Saf. 2017;26:81–90.PubMedCrossRefGoogle Scholar
  79. 79.
    Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12:20.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Sweileh WM, et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav. 2011;21:301–5.PubMedCrossRefGoogle Scholar
  81. 81.
    De las Cuevas C, Penate W, Sanz EJ. Risk factors for non-adherence to antidepressant treatment in patients with mood disorders. Eur J Clin Pharmacol. 2014;70:89–98.CrossRefGoogle Scholar
  82. 82.
    Cooper DC, et al. Antidepressant adherence and risk of coronary artery disease hospitalizations in older and younger adults with depression. J Am Geriatr Soc. 2014;62:1238–45.PubMedCrossRefGoogle Scholar
  83. 83.
    Hashmi SK, et al. Factors associated with adherence to anti-hypertensive treatment in Pakistan. PLoS One. 2007;2:e280.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Li WW, Kuo CT, Hwang SL, Hsu HT. Factors related to medication non-adherence for patients with hypertension in Taiwan. J Clin Nurs. 2012;21:1816–24.PubMedCrossRefGoogle Scholar
  85. 85.
    Holt E, et al. Sex differences in barriers to antihypertensive medication adherence: findings from the cohort study of medication adherence among older adults. J Am Geriatr Soc. 2013;61:558–64.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Wang W, Lau Y, Loo A, Chow A, Thompson DR. Medication adherence and its associated factors among Chinese community-dwelling older adults with hypertension. Heart Lung. 2014;43:278–83.PubMedCrossRefGoogle Scholar
  87. 87.
    Agh T, Inotai A, Meszaros A. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011;82:328–34.PubMedCrossRefGoogle Scholar
  88. 88.
    Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin Ther. 2010;32:1320–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Jansa M, et al. Multidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospital. Patient Educ Couns. 2010;81:161–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Tsai KT, et al. Medication adherence among geriatric outpatients prescribed multiple medications. Am J Geriatr Pharmacother. 2012;10:61–8.PubMedCrossRefGoogle Scholar
  91. 91.
    Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004;351:2870–4.PubMedCrossRefGoogle Scholar
  92. 92.
    Qvarnstrom M, et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol. 2013;69:1955–64.CrossRefPubMedGoogle Scholar
  93. 93.
    Hasford J, Schroder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol. 2007;63:1055–61.PubMedCrossRefGoogle Scholar
  94. 94.
    Morris AB, et al. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy. 2006;26:483–92.PubMedCrossRefGoogle Scholar
  95. 95.
    Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging. 2008;25:885–92.PubMedCrossRefGoogle Scholar
  96. 96.
    Wong MC, et al. The association between multimorbidity and poor adherence with cardiovascular medications. Int J Cardiol. 2014;177:477–82.PubMedCrossRefGoogle Scholar
  97. 97.
    Wong MC, et al. Factors associated with multimorbidity and its link with poor blood pressure control among 223,286 hypertensive patients. Int J Cardiol. 2014;177:202–8.PubMedCrossRefGoogle Scholar
  98. 98.
    Calderon-Larranaga A, et al. Non-adherence to antihypertensive medication: the role of mental and physical comorbidity. Int J Cardiol. 2016;207:310–6.PubMedCrossRefGoogle Scholar
  99. 99.
    Saadat Z, et al. Adherence to antihypertensives in patients with comorbid condition. Nephrourol Mon. 2015;7:e29863.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Stewart M, Fortin M, Britt HC, Harrison CM, Maddocks HL. Comparisons of multi-morbidity in family practice—issues and biases. Fam Pract. 2013;30:473–80.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    James PA, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.PubMedCrossRefGoogle Scholar
  102. 102.
    Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peterson ED. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA. 2014;311:1424–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Anderson JL, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329–45.PubMedCrossRefGoogle Scholar
  104. 104.
    Moran AE, et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015;372:447–55.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Abraham JM. Using microsimulation models to inform U.S. health policy making. Health Serv Res. 2013;48:686–95.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Fontil V, et al. Simulating strategies for improving control of hypertension among patients with usual source of Care in the United States: the blood pressure control model. J Gen Intern Med. 2015;30:1147–55.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Jha AK. Learning from the past to improve VA health care. JAMA. 2016;315:560–1.PubMedCrossRefGoogle Scholar
  108. 108.
    Rumsfeld JS, Joynt KE, Maddox TM. Big data analytics to improve cardiovascular care: promise and challenges. Nat Rev Cardiol. 2016;13:350–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Hussey PS, Eibner C, Ridgely MS, McGlynn EA. Controlling U.S. health care spending—separating promising from unpromising approaches. N Engl J Med. 2009;361:2109–11.PubMedCrossRefGoogle Scholar
  110. 110.
    Fields D, Leshen E, Patel K. Analysis & commentary. Driving quality gains and cost savings through adoption of medical homes. Health Aff (Millwood). 2010;29:819–26.CrossRefGoogle Scholar
  111. 111.
    Rosenthal MB, et al. Will the patient-centered medical home improve efficiency and reduce costs of care? A measurement and research agenda. Med Care Res Rev. 2010;67:476–84.PubMedCrossRefGoogle Scholar
  112. 112.
    Peikes D, Zutshi A, Genevro JL, Parchman ML, Meyers DS. Early evaluations of the medical home: building on a promising start. Am J Manag Care. 2012;18:105–16.PubMedGoogle Scholar
  113. 113.
    Sidorov JE. The patient-centered medical home for chronic illness: is it ready for prime time? Health Aff (Millwood). 2008;27:1231–4.CrossRefGoogle Scholar
  114. 114.
    Beadles CA, et al. Do medical homes increase medication adherence for persons with multiple chronic conditions? Med Care. 2015;53:168–76.PubMedCrossRefGoogle Scholar
  115. 115.
  116. 116.
    Committee on Quality of Health Care in America, Institute of Medicine. To err is human: building a safer health system. Washington, DC: National Academies Press; 2000.Google Scholar
  117. 117.
    Baker GR, et al. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. CMAJ. 2004;170:1678–86.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
  119. 119.
    Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652–8.PubMedCrossRefGoogle Scholar
  120. 120.
    Turgeon J, Michaud V. Clinical decision support systems: great promises for better management of patients’ drug therapy. Expert Opin Drug Metab Toxicol. 2016;12:993–5.PubMedCrossRefGoogle Scholar
  121. 121.
    Zakrzewski-Jakubiak H, et al. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software. Am J Geriatr Pharmacother. 2011;9:461–70.PubMedCrossRefGoogle Scholar
  122. 122.
    Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013;47:324–32.PubMedCrossRefGoogle Scholar
  123. 123.
    Wang L. Physician-related barriers to hypertension management. Med Princ Pract. 2004;13:282–5.PubMedCrossRefGoogle Scholar
  124. 124.
    Mehta SS, Wilcox CS, Schulman KA. Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP). Am J Hypertens. 1999;12:333–40.PubMedGoogle Scholar
  125. 125.
    Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med. 2000;160:2281–6.PubMedCrossRefGoogle Scholar
  126. 126.
    Milchak JL, Carter BL, James PA, Ardery G. Measuring adherence to practice guidelines for the management of hypertension: an evaluation of the literature. Hypertension. 2004;44:602–8.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    McAlister FA, O’Connor AM, Wells G, Grover SA, Laupacis A. When should hypertension be treated? The different perspectives of Canadian family physicians and patients. CMAJ. 2000;163:403–8.PubMedPubMedCentralGoogle Scholar
  128. 128.
    Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479–86.PubMedCrossRefGoogle Scholar
  129. 129.
    Ragot S, Beneteau M, Guillou-Bonnici F, Herpin D. Prevalence and management of hypertensive patients in clinical practice: cross-sectional registry in five countries outside the European Union. Blood Press. 2016;25:104–16.PubMedCrossRefGoogle Scholar
  130. 130.
    EUGenMed Cardiovascular Clinical Study Group, et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016;37:24–34.CrossRefGoogle Scholar
  131. 131.
    Al-Ansary LA, et al. A systematic review of recent clinical practice guidelines on the diagnosis, assessment and management of hypertension. PLoS One. 2013;8:e53744.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Cai L, Liu A, Zhang L, Li S, Wang P. Prevalence, awareness, treatment, and control of hypertension among adults in Beijing, China. Clin Exp Hypertens. 2012;34:45–52.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Whelton PK, He J, Muntner P. Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. J Hum Hypertens. 2004;18:545–51.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Alsuwaida A, Alghonaim M. Gender disparities in the awareness and control of hypertension. Clin Exp Hypertens. 2011;33:354–7.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167:141–7.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Fervers B, et al. Predictors of high quality clinical practice guidelines: examples in oncology. Int J Qual Health Care. 2005;17:123–32.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Watine J, et al. Conflict between guideline methodologic quality and recommendation validity: a potential problem for practitioners. Clin Chem. 2006;52:65–72.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    Nagy E, et al. Do guidelines for the diagnosis and monitoring of diabetes mellitus fulfill the criteria of evidence-based guideline development? Clin Chem. 2008;54:1872–82.PubMedCrossRefPubMedCentralGoogle Scholar
  139. 139.
    Tai-Seale M, McGuire TG, Zhang W. Time allocation in primary care office visits. Health Serv Res. 2007;42:1871–94.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? Am J Public Health. 2003;93:635–41.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Maciosek MV, et al. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006;31:52–61.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Ostbye T, et al. Is there time for management of patients with chronic diseases in primary care? Ann Fam Med. 2005;3:209–14.PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    Flocke SA, Frank SH, Wenger DA. Addressing multiple problems in the family practice office visit. J Fam Pract. 2001;50:211–6.PubMedGoogle Scholar
  144. 144.
    Fiscella K, Epstein RM. So much to do, so little time: care for the socially disadvantaged and the 15-minute visit. Arch Intern Med. 2008;168:1843–52.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Pimlott N. Preventive care: so many recommendations, so little time. CMAJ. 2005;173:1345–6.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Tarn DM, et al. How much time does it take to prescribe a new medication? Patient Educ Couns. 2008;72:311–9.PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Hadley J, Mitchell JM, Sulmasy DP, Bloche MG. Perceived financial incentives, HMO market penetration, and physicians’ practice styles and satisfaction. Health Serv Res. 1999;34:307–21.PubMedPubMedCentralGoogle Scholar
  148. 148.
    Nutting PA, Rost K, Smith J, Werner JJ, Elliot C. Competing demands from physical problems: effect on initiating and completing depression care over 6 months. Arch Fam Med. 2000;9:1059–64.PubMedCrossRefGoogle Scholar
  149. 149.
    Linzer M, et al. Managed care, time pressure, and physician job satisfaction: results from the physician worklife study. J Gen Intern Med. 2000;15:441–50.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Mechanic D. Physician discontent: challenges and opportunities. JAMA. 2003;290:941–6.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Nutting PA, et al. Competing demands in the office visit: what influences mammography recommendations? J Am Board Fam Pract. 2001;14:352–61.PubMedPubMedCentralGoogle Scholar
  152. 152.
    Taksler GB, Keshner M, Fagerlin A, Hajizadeh N, Braithwaite RS. Personalized estimates of benefit from preventive care guidelines: a proof of concept. Ann Intern Med. 2013;159:161–8.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29:725–31.PubMedCrossRefPubMedCentralGoogle Scholar
  154. 154.
    O’Connor PJ. Setting evidence-based priorities for diabetes care improvement. Int J Qual Health Care. 2003;15:283–5.PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    Braithwaite RS, Concato J, Chang CC, Roberts MS, Justice AC. A framework for tailoring clinical guidelines to comorbidity at the point of care. Arch Intern Med. 2007;167:2361–5.PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296:2336–42.PubMedCrossRefPubMedCentralGoogle Scholar
  157. 157.
    Melgarejo JD, et al. Prevalence, treatment, and control rates of conventional and ambulatory hypertension across 10 populations in 3 continents. Hypertension. 2017;70:50–8.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Faculty of PharmacyUniversity of MontrealMontrealCanada

Personalised recommendations